I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.

Histogenics Corporation (HSGX), Receipt of $10 Million Up-front Payment for Japanese Neocart Agreement

January 9, 2018

HSGX had closed up + $0.02 to $2.24, the pre-market indication is +$0.08 or +3.57% - BUY

Takeda Pharmaceutical intents to acquire TiGenix (Brussels and NASDAQ: TIG)

January 5, 2018

Takeda intends to acquire 100% of the securities with voting rights or giving access to voting rights of TiGenix not already owned by Takeda or affiliates at a price of EUR 1.78 per share in cash and an equivalent price in cash per American Depositary Share, warrant and convertible bond.

Sangamo Therapeutics (SGMO) $12 million collaboration with Pfizer (PFE) on a gene therapy for two neuro-degenerative disorders

January 3, 2018

SGMO closed up +$1.15 or 7.01% to $17.55 with a pre-market indication is a positive +$0.60 or +3.39% after news of the company's $12 million collaboration with Pfizer (PFE) on a gene therapy for two neurodegenerative disorders, amyotrophic lateral sclerosis and frontotemporal lobar degeneration. 

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.